MAB1645
Anti-Dystrophin Antibody
CHEMICON®, mouse monoclonal, 1808
동의어(들):
Anti-BMD, Anti-CMD3B, Anti-DXS142, Anti-DXS164, Anti-DXS206, Anti-DXS230, Anti-DXS239, Anti-DXS268, Anti-DXS269, Anti-DXS270, Anti-DXS272, Anti-MRX85
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
UNSPSC 코드:
12352203
eCl@ss:
32160702
NACRES:
NA.41
제품 MAB1645은(는)귀하의 국가에서 현재 판매되지 않습니다. 고객지원팀으로 연락바랍니다.
추천 제품
제품명
Anti-Dystrophin Antibody, clone 1808, clone 1808, Chemicon®, from mouse
생물학적 소스
mouse
Quality Level
항체 형태
purified antibody
항체 생산 유형
primary antibodies
클론
1808, monoclonal
종 반응성
chicken, mouse, rat, human
제조업체/상표
Chemicon®
기술
immunohistochemistry: suitable
western blot: suitable
동형
IgG1
NCBI 수납 번호
UniProt 수납 번호
배송 상태
dry ice
타겟 번역 후 변형
unmodified
유전자 정보
human ... DMD(1756)
특이성
By Western blot MAB1645 recognizes a single protein having a relative molecular weight of 300 kD. Reacts to mammalian skeletal muscle dystrophin. Shows no staining of mdx mouse muscle. Labels normal human muscle but not Duchenne muscle.
STAINING PATTERN:
On cryostat sections of normal mouse diaphragm MAB1645 gives strong immunofluorescence staining of the entire sarcolemma, with particularly strong staining of neuromuscular junctions.
SPECIES REACTIVITY:
Labels skeletal muscle from rat, chicken and Xenopus laevis. Labels cardiac muscle from rat and normal, but not mdx, mouse. Also labels smooth muscle from chicken gizzard.
STAINING PATTERN:
On cryostat sections of normal mouse diaphragm MAB1645 gives strong immunofluorescence staining of the entire sarcolemma, with particularly strong staining of neuromuscular junctions.
SPECIES REACTIVITY:
Labels skeletal muscle from rat, chicken and Xenopus laevis. Labels cardiac muscle from rat and normal, but not mdx, mouse. Also labels smooth muscle from chicken gizzard.
면역원
Peripheral membrane proteins extracted from Torpedo postsynaptic membranes.
애플리케이션
Anti-Dystrophin Antibody, clone 1808 detects level of Dystrophin & has been published & validated for use in WB, IH.
Western blot
Immunohistochemistry
Optimal working dilutions must be determined by the end user.
Immunohistochemistry
Optimal working dilutions must be determined by the end user.
물리적 형태
Format: Purified
Liquid in 0.02 M phosphate buffer (pH 7.6), 250 mM NaCl with 0.1% sodium azide.
저장 및 안정성
Maintain at -20ºC for up to 12 months in convenient aliquots. Avoid repeated freeze/thaw cycles.
법적 정보
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
적합한 제품을 찾을 수 없으신가요?
당사의 제품 선택기 도구.을(를) 시도해 보세요.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Andreas Schaefer et al.
PloS one, 11(2), e0148259-e0148259 (2016-02-04)
Previous small animal models for simulation of mechanical unloading are solely performed in healthy or infarcted hearts, not representing the pathophysiology of hypertrophic and dilated hearts emerging in heart failure patients. In this article, we present a new and economic
Andreas Schaefer et al.
Scientific reports, 9(1), 5710-5710 (2019-04-07)
Mechanical unloading (MU) by implantation of left ventricular assist devices (LVAD) has become clinical routine. This procedure has been shown to reverse cardiac pathological remodeling, with the underlying molecular mechanisms incompletely understood. Most studies thus far were performed in non-standardized
Mariana Fernandez-Caggiano et al.
Nature metabolism, 2(11), 1223-1231 (2020-10-28)
Cardiomyocytes rely on metabolic substrates, not only to fuel cardiac output, but also for growth and remodelling during stress. Here we show that mitochondrial pyruvate carrier (MPC) abundance mediates pathological cardiac hypertrophy. MPC abundance was reduced in failing hypertrophic human
Tessa R Werner et al.
Scientific reports, 9(1), 11494-11494 (2019-08-09)
Afterload enhancement (AE) of rat engineered heart tissue (EHT) in vitro leads to a multitude of changes that in vivo are referred to as pathological cardiac hypertrophy: e.g., cardiomyocyte hypertrophy, contractile dysfunction, reactivation of fetal genes and fibrotic changes. Moreover
Payam Soltanzadeh et al.
Neuromuscular disorders : NMD, 20(8), 499-504 (2010-07-16)
Manifesting carriers of DMD gene mutations may present diagnostic challenges, particularly in the absence of a family history of dystrophinopathy. We review the clinical and genetic features in 15 manifesting carriers identified among 860 subjects within the United Dystrophinopathy Project
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
